DiRaimondo Thomas 4
4 · Janux Therapeutics, Inc. · Filed Jan 3, 2024
Insider Transaction Report
Form 4
DiRaimondo Thomas
Chief Scientific Officer
Transactions
- Award
Stock Option (right to buy)
2024-01-02+147,000→ 147,000 totalExercise: $11.02Exp: 2034-01-01→ Common Stock (147,000 underlying)
Footnotes (1)
- [F1]25% of the shares subject to the option vest on January 1, 2025 and the balance will vest in equal monthly installments thereafter over a three year period.